Cisbio Bioassays

Cisbio Bioassays develops and markets products and technologies used for in vitro diagnostics and drug discovery. With its proprietary technology, HTRF®, the company is a leader in homogeneous fluorescence detection methods, and offers first class assays and services for drug discovery researchers. In addition, Cisbio Bioassays provides a broad range of immunoassays for in vitro diagnostics, mainly tailored for cancerous pathologies, as well as metabolic and auto-immune diseases.

Based in Codolet, France, Cisbio Bioassays owns facilities in Bedford, MA, U.S.A., and Shanghai, China, and markets its global offer through a network of distributors.

Guide: A comprehensive overview of the autoimmunity world

Guide: Molecular basis of neuroinflammation and neurodegeneration

Literature review: A review to cross the hurdle of drug discovery with PROTACs

Guide: Immunology basics

Guide: Protein-protein interaction assay now made easy with this complete user’s guide

Whitepaper: Accelerating Gαq GPCR Drug Discovery with recognized and reliable tool

Technical note: The way to success for GPCR signaling studies – 5 expert tips to boost ERK assay performance

App note: Struggling with ERK phosphorylation in GPCR research?

App note: HTRF technology essentials to boost your research

Expert view: Understanding the fast-evolving immune-oncology landscape

Kick-starting the immune response – the shifting landscape of immuno-oncology

Under the microscope with Joseph Jammal, Chief Operating Officer of Cisbio Bioassays

Biased ligands in Drug Discovery – the case of TRV027